Liaoning Chengda Biotechnology Co.,Ltd.

688739

CNE100004ZP2

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 2026-03-10			5-day change	1st Jan Change
25.52 ^CNY	+0.87%		-0.20%	-0.93%

07:04am	Chengda Biotechnology Unit Passes China Provincial-Level GMP Standards for Human Rabies Vaccine Workshop	MT
Feb. 27	Liaoning Chengda Biotechnology Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

China Approves Trials for Liaoning Chengda Biotechnology's High-Dose Flu Jab

Published on 02/13/2026 at 04:25 am EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Liaoning Chengda Biotechnology Co.,Ltd.

07:04am	Chengda Biotechnology Unit Passes China Provincial-Level GMP Standards for Human Rabies Vaccine Workshop	MT
Feb. 27	Liaoning Chengda Biotechnology Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Feb. 13	China Approves Trials for Liaoning Chengda Biotechnology's High-Dose Flu Jab	MT
Feb. 12	Liaoning Chengda Biotechnology's board elects co-chairman	RE
Feb. 05	Liaoning Chengda Biotechnology plans to jointly set up industry investment fund	RE
Jan. 27	Liaoning Chengda Biotechnology Expects Up to 64% Fall in 2025 Profit	MT
Jan. 05	Tranche Update on Liaoning Chengda Biotechnology Co.,Ltd.'s Equity Buyback Plan announced on June 20, 2025.	CI
Dec. 05	Chengda Biotechnology Co., Ltd. announced that it has received CNY 100 million in funding from Liaoning Chengda Biotechnology Co.,Ltd.	CI
25-10-29	Liaoning Chengda Biotechnology Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-10-22	Chengda Biotechnology Ties Up With Educational Institution to Develop Vector-Borne Disease Prevention Drugs	MT
25-10-09	Tranche Update on Liaoning Chengda Biotechnology Co.,Ltd.'s Equity Buyback Plan announced on June 20, 2025.	CI
25-08-28	Liaoning Chengda Biotechnology Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-06-20	Chengda Biotechnology to Buy Back Shares of Up to 20 Million Yuan	MT
25-06-19	Liaoning Chengda Biotechnology Co.,Ltd. announces an Equity Buyback for CNY 20 million worth of its shares.	CI
25-06-18	Liaoning Chengda Biotechnology Co.,Ltd. authorizes a Buyback Plan.	CI

Chart Liaoning Chengda Biotechnology Co.,Ltd.

Duration

Period

Chart Liaoning Chengda Biotechnology Co.,Ltd.

688739: Dynamic Chart

Liaoning Chengda Biotechnology Co Ltd is a China-based company mainly engaged in the research and development, production and sales of human vaccines. The Company's products include rabies vaccine for human use and inactivated Japanese encephalitis vaccine. The Company has completed the construction of bacterial vaccine technology platform, viral vaccine technology platform, multi-component multivalent vaccine technology platform and recombinant protein vaccine technology platform. The Company mainly conducts its businesses in the domestic and foreign markets.

Employees

1,807

Sector

Pharmaceuticals

Calendar

Apr. 21 - Earnings release - Annual 2025

More about the company